Objective
The purpose of this study was to describe relations among maternal demographic and
lifestyle characteristics and midpregnancy levels of angiogenic markers (soluble Fms-like
tyrosine kinase-1, placental growth factor, soluble endoglin).
Study Design
In a large pregnancy cohort, linear models were used to evaluate relations among maternal
characteristics and midpregnancy angiogenic markers with and without covariate adjustment.
Associations were examined in a subcohort that included term and preterm deliveries
(n = 1302) and among “normal” term pregnancies (n = 668).
Results
Concentrations of all factors declined with increasing maternal body mass index. Multiparous
women had lower soluble Fms-like tyrosine kinase-1 levels than primiparous women.
Higher placental growth factor and slightly lower soluble endoglin levels were observed
among women who smoked at enrollment, but not among those women who quit before enrollment.
African American women had higher levels of all markers.
Conclusion
Understanding relations among maternal characteristics and levels of angiogenic factors
may improve studies that use these markers to examine etiology and/or to predict adverse
pregnancy outcome.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.J Matern Fetal Neonatal Med. 2008; 21: 9-23
- Preeclampsia: the role of angiogenic factors in its pathogenesis.Physiology (Bethesda). 2009; 24: 147-158
- Circulating soluble endoglin and placental abruption.Prenat Diagn. 2008; 28: 852-858
- Medically indicated preterm birth: recognizing the importance of the problem.Clin Perinatol. 2008; 35: 53-67
- Circulating angiogenic factors and the risk of preeclampsia.N Engl J Med. 2004; 350: 672-683
- Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.N Engl J Med. 2006; 355: 992-1005
- Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth and stillbirth.Obstet Gynecol. 2007; 109: 1316-1324
- A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study.J Matern Fetal Neonatal Med. 2009; 22: 1122-1139
- Circulating angiogenic factors in gestational proteinuria without hypertension.Am J Obstet Gynecol. 2009; 200: 10
- Unexplained fetal death: another anti-angiogenic state.J Matern Fetal Neonatal Med. 2007; 20: 495-507
- Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders.J Thromb Haemost. 2003; 1: 1356-1370
- Thrombin regulates soluble Fms-like tyrosine kinase-1 (sflt-1) expression in first trimester decidua.Am J Pathol. 2007; 170: 1398-1405
- Extra-placental expression of vascular endothelial growth factor receptor-1, (flt-1) and soluble flt-1 (sfit-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women.Placenta. 2005; 26: 563-573
- Vasculogenesis and angiogenesis in the early human placenta.Acta Histochemica. 2007; 109: 257-265
- Angiogenic imbalances: the obstetric perspective.Am J Obstet Gynecol. 2010; 203: 17.e1-17.e8
- First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.J Clin Endocrinol Metab. 2004; 89: 770-775
- Soluble endoglin contributes to the pathogenesis of preeclampsia.Nat Med. 2006; 12: 642-649
- Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia.Am J Obstet Gynecol. 2007; 196: 239.e1-239.e6
- Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia.Hypertension. 2007; 50: 35-36
- Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.Eur J Obstet Gynecol Reprod Biol. 2009; 143: 29-33
- First-trimester prediction of hypertensive disorders in pregnancy.Hypertension. 2009; 53: 812-818
- Maternal serum soluble Fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.Am J Obstet Gynecol. 2005; 193: 185-191
- Excess placental soluble Fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.J Clin Invest. 2003; 111: 649-658
- Circulating levels of the antiangiogenic marker sflt-1 are increased in first versus second pregnancies.Am J Obstet Gynecol. 2005; 193: 16-22
- Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia.Placenta. 2008; 29: 555-563
- Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of preeclampsia.Ultrasound Obstet Gynecol. 2008; 32: 732-739
- A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.J Matern Fetal Neonatal Med. 2009; 22: 1021-1038
- Biomarkers for the prediction of preterm delivery.Acta Obstet Gynecol Scand. 2005; 84: 516-525
- Significance of raised maternal serum alpha-fetoprotein in singleton pregnancies with normally formed fetuses.Obstet Gynecol. 1985; 65: 465-470
- Midpregnancy vaginal fluid defensins, bacterial vaginosis and risk of preterm delivery.Obstet Gynecol. 2008; 112: 524-531
- A United States national reference for fetal growth.Obstet Gynecol. 1996; 87: 163-168
- About BMI for Adults, 2009 (vol 2010).(Accessed June 7, 2010)
- Pre-eclampsia.Lancet. 2005; 365: 785-799
- Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review.Obstet Gynecol. 2007; 109: 168-180
- Effect of long-term storage on placental growth factor and Fms-like tyrosine kinase 1 measurements in samples from pregnant women.J Matern Fetal Neonatal Med. 2010; 23: 1475-1480
- The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications.Obstet Gynecol. 1996; 88: 816-822
- Refinements in managing maternal weight adjustment for interpreting prenatal screening results.Prenat Diagn. 1996; 16: 1115-1119
- Levels of maternal serum corticotrophin-releasing hormone (CRH) at midpregnancy in relation to maternal characteristics.Psychoneuroendocrinology. 2010; 35: 820-832
- Plasma volume expansion in pregnancy: implications for biomarkers in population studies.Cancer Epidemiol Biomarkers Prev. 2007; 16: 1720-1723
- Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction.Hypertension. 2006; 47: 203-208
- Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia.Am J Obstet Gynecol. 2006; 195: 40-49
- Interactions between smoking and weight in pregnancies complicated by preeclampsia and small-for-gestational-age birth.Am J Epidemiol. 2008; 168: 427-433
- Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review.Am J Obstet Gynecol. 1999; 181: 1026-1035
- Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.Am J Hypertens. 2008; 21: 943-947
- Circulating angiogenic factors in smokers and non-smokers during normotensive pregnancy.Am J Obstet Gynecol. 2006; 195: S37
- Serum sflt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women.Am J Obstet Gynecol. 2006; 194: 1034-1041
- How does smoking reduce the risk of preeclampsia?.Hypertension. 2010; 55: 1100-1101
- Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes.Nicotine Tob Res. 2007; 9: 1005-1013
- Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff.Hypertension. 2010; 55: 1254-1259
- A multivariate analysis of risk factors for preeclampsia.JAMA. 1991; 266: 237-241
- Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.Hypertension. 2007; 50: 137-142
- The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.J Matern Fetal Neonatal Med. 2008; 21: 279-287
Article info
Publication history
Published online: December 13, 2010
Accepted:
October 7,
2010
Received in revised form:
September 14,
2010
Received:
June 14,
2010
Footnotes
Cite this article as: Mijal RS, Holzman CB, Rana S, et al. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244.e1-12.
Reprints not available from the authors.
Supported by the March of Dimes Foundation (Grant nos. 20FY01-38 and 20-FY04-37), the National Institute of Child Health and Human Development and the National Institute of Nursing Research (Grant no. R01 HD34543), the Thrasher Research Foundation (Grant no. 02816-7), Diabetes UK (Grant no. RD 05-0003099), and the Centers for Disease Control and Prevention (Grant no. U01 DP000143-01), awarded to C.B.H. R.S.M. is supported by an Institutional T32 grant (Grant no. T32 HD046377) in Perinatal Epidemiology awarded to Michigan State University. S.R. is supported by a Women's Reproductive Health Research Award (5K12HD001255- NIH/NICHD). S.A.K. is an investigator at the Howard Hughes Medical Institute.
Dr Karumanchi is a listed as a co-inventor on multiple patents assigned to the Beth Israel Deaconess Medical Center that are related to the diagnosis and therapy of preeclampsia. These patents have been licensed nonexclusively to multiple companies. He is also a consultant to Abbott, Beckman Coulter, Johnson & Johnson and Roche diagnostics.
Identification
Copyright
© 2011 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- CorrectionAmerican Journal of Obstetrics & GynecologyVol. 205Issue 1
